Ph.D. Noubar B. Afeyan - 18 May 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNA	Common Stock	Sale	$1,383,800	-10,000	-0.39%	$138.38	2,567,209	18 May 2022	Direct	F1, F2
holding	MRNA	Common Stock						12,882,819	18 May 2022	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.	F3
holding	MRNA	Common Stock						3,924	18 May 2022	By Flagship Pioneering, Inc.	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2021, as amended on March 11, 2022.
F2	Includes shares received in prior distributions-in-kind from Flagship VentureLabs IV LLC ("VentureLabs IV"), Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Fund Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") and Flagship Fund IV General Partner LLC ("Flagship Fund IV GP") made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
F3	10,801,059 shares are held directly by Flagship Fund IV (which reflects prior distributions-in-kind from VentureLabs IV) and 2,081,760 shares are held directly by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F4	3,924 shares are held directly by Flagship Pioneering, Inc. ("Flagship Pioneering"). The reporting person is the CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.